Non-small-cell lung cancer (NSCLC) is globally prevalent and associated with high rates of mortality. Immune checkpoint pathways are often exploited by tumors to evade immunity-mediated destruction, and checkpoint inhibitors can reactivate tumor-related immune responses. This review considers available clinical evidence for the use of checkpoint inhibitors in the treatment of second-line advanced NSCLC.
Methods
Our systematic search revealed 20 clinical trials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized trials comparing programmed cell death protein 1 and programmed death ligand 1 (PD-L1) inhibitors to docetaxel, the current standard of care in this setting.
Results
A randomized phase II trial comparing the PD-L1 inhibitor atezolizumab to docetaxel did not demonstrate improved survival for atezolizumab in patients overall, although a trend toward improved survival with increased PD-L1 expression was apparent. Twin phase III trials showed significantly improved survival for the programmed cell death protein 1 inhibitor nivolumab compared with docetaxel in patients with both squamous and nonsquamous disease. PD-L1 expression correlated with improved survival in patients with nonsquamous disease, and patients with low levels of PD-L1 expression (, 10%) and those with EGFR mutations are unlikely to benefit. Checkpoint inhibitor therapy is generally well tolerated and associated with low rates of grade 3 or 4 adverse events compared with standard care.
INTRODUCTION
An estimated 1.8 million new cases of lung cancer occurred in 2012, accounting for approximately 13% of total cancer diagnoses and a mortality rate of nearly 90%, making lung cancer the leading cause of cancer-related deaths in men and the second leading cause in women worldwide. 1 Approximately 70% of patients with lung cancer present with advanced disease. 2 Approximately 85% of lung cancers are classified as non-small-cell lung cancer (NSCLC; 10% to 15% small cell), 3, 4 and approximately 70% of these have a nonsquamous histology. 5 In addition, between 5% and 45% of NSCLCs have targetable driver mutations such as epidermal growth factor receptor (EGFR) mutations (tyrosine kinase inhibitors) or anaplastic lymphoma kinase (ALK) translocations (ALK inhibitors). 6 Treatment of advanced NSCLC has evolved rapidly, with targeted therapies replacing firstline chemotherapy 7, 8 or enhancing maintenance strategies 9, 10 in select patients. In second-line treatment, the traditional standard of care remains docetaxel in patients with squamous tumors or those with nonsquamous tumors and a nontargetable or unknown mutation status, 8, 11, 12 although the addition of ramucirumab 13, 14 or use of pemetrexed may also be applied in select patients. 8, 12 Platinum-based doublets 8 are a second-line option for patients with EGFR mutations, and ceritinib is indicated for those with ALK rearrangements after progression on crizotinib. 15, 16 Despite these innovations, the inevitable progression of patients receiving second-line therapy requires new approaches that are widely applicable to extend survival, minimize toxicity, and improve quality of life. The human immune system is an effective means of fighting cancer, 17, 18 and the development of therapeutics that harness the power of natural immunity to combat malignant growth has been an ongoing goal of cancer research. [19] [20] [21] More recently, connections between checkpoint pathways and cancer immunity have presented new opportunities for clinical development. 22 The immune response against cancer cells occurs through T-cell activation and regulation. 23 In lymphatic tissue, T cells are activated by the antigen-presenting cell ( Fig 1A) and then circulate to peripheral tissues, seeking out and attacking antigen-expressing tumor cells ( Fig 1B) . There are myriad mechanisms that negatively regulate T-cell responses to prevent potentially destructive autoimmune activity. 18, 22 In lymphatic tissue, expression of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) negatively regulates the early stages of T-cell activation by competing with the T-cell costimulatory receptor CD28 for binding with CD80 and CD86 expressed on the antigen-presenting cell ( Fig 1A) . 17 Antibody blockade of CTLA-4 has been shown to increase antitumor immunity in preclinical 24 and clinical settings. 25, 26 In peripheral tissues ( Fig 1B) , the effector phase of the adaptive immune response against tumor cells is negatively regulated in part through binding of the programmed cell death protein 1 (PD-1) expressed on activated T cells with the programmed death ligand 1 (PD-L1) and/or programmed death ligand 2 (PD-L2). 27 Tumor cells can evade the immune response through the upregulated expression of PD-L1, 22 leading to downregulation of T-cell responses and immune resistance. PD-1 and PD-L1 inhibitors can re-engage T-cell activity in peripheral tissues by blocking PD-1 binding to PD-L1 (PD-L1 inhibitors) or to both PD-L1 and PD-L2 (PD-1 inhibitors). 28 The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been approved for the Immune system activation and regulation in the antitumor response. APC, antigenpresenting cell; CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; PD-L1/2, programmed death ligand 1/2; TCR, T-cell receptor. treatment of melanoma. Eight checkpoint inhibitors (two CTLA-4 inhibitors, two PD-1 inhibitors, and four PD-L1 inhibitors) are currently under development for NSCLC (Table 1) , and although anti-CTLA-4 agents were the first checkpoint inhibitors to be evaluated in NSCLC, 29,30 the PD-1 inhibitors are furthest along in development for second-line disease. Two checkpoint inhibitors have now received US Food and Drug Administration approval for use in advanced NSCLC, nivolumab for use in patients with squamous disease (March 4, 2015) and pembrolizumab for use in patients with tumors that express PD-L1 as assessed with the IHC 22C3 pharmDx assay (Dako, Carpinteria, CA; October 2, 2015) . 31, 32 This article considers available evidence on checkpoint inhibition as second-line therapy for advanced NSCLC, with the purpose of providing clear guidance on its use in clinical practice.
METHODS
Recent studies investigating checkpoint inhibitors for NSCLC were identified and reviewed. PubMed (to May 21, 2015) and the proceedings of the ASCO (2014 to 2015) and European Society for Medical Oncology (2014) annual meetings were searched using the following key search terms (or aliases): non-small-cell lung cancer AND immune checkpoint inhibitors (OR respective aliases). A supplemental bibliographic search of recent review articles and directed searches for updated reports of specific studies was also conducted. Records were vetted, and only the most current published or presented second-line clinical trial reports were included in this analysis (Appendix Fig A1, online only) .
RESULTS
The literature search produced a total of 252 records representing 20 clinical trials investigating immune checkpoint inhibitors in second-line NSCLC, all of which assessed PD-1/PD-L1 inhibitors (Appendix Fig A1) .
Nivolumab (PD-1)
Phase I and II trials. Two phase I trials 33,34 and three phase II  trials 35,36 have demonstrated the activity and safety of nivolumab as  a single agent in both squamous and nonsquamous previously  treated advanced NSCLC (Table 2 ). The largest of the phase II trials, the CheckMate 063 study (n = 117), evaluated nivolumab at the phase I established dose of 3 mg/kg every 2 weeks, reporting an objective response rate (ORR) of 14.5%, a median overall survival (OS) of 8.2 months, and treatment-related grade 3 or 4 adverse events (AEs) in 17% of heavily pretreated patients with squamous histology treated with nivolumab. 36 Similar results were also confirmed in two smaller Japanese trials. 35 Phase III trial. On the basis of these promising findings, twin open-label randomized phase III trials compared single-agent nivolumab 3 mg/kg every 2 weeks with docetaxel 75 mg/m 2 every 3 weeks in patients with previously treated squamous and nonsquamous stage III or IV NSCLC ( Table 2 ). 37,37a The first trial, CheckMate 017, was conducted in 272 good performance patients with squamous NSCLC. 37 The primary end point was OS. A preplanned interim analysis demonstrated a median OS of 9.2 months in the nivolumab arm compared with 6.0 months in the docetaxel group (hazard ratio [HR], 0.59; 95% CI, 0.44 to 0.79; P ,.001) and an improved 1-year OS rate for nivolumab compared with docetaxel (42% v 24%, respectively; Table 2 ). The ORR and median progression-free survival (PFS) were also significantly improved for nivolumab compared with docetaxel (ORR, 20% v 9%, respectively; P = .008; and PFS, 3.5 v 2.8 months, respectively; HR, 0.62; 95% CI, 0.47 to 0.81; P , .001). The median duration of response (DOR) was not reached in the nivolumab arm (range, 2.9 to 20.5+ months) compared with a DOR of 8.4 months in the docetaxel arm. Across prespecified expression levels (1%, 5%, and 10%), PD-L1 was neither prognostic nor predictive of any efficacy end points (Table 3 ). Treatment-related AEs of any grade occurred in 58% of patients receiving nivolumab and 86% of patients receiving docetaxel ( Table 4 ). Rates of grade 3 or 4 treatment-related AEs were considerably lower in the nivolumab arm (7%) compared with the docetaxel arm (55%). The most common AEs of any grade reported for nivolumab were fatigue (16%), decreased appetite (11%), and asthenia (10%). Pneumonitis was reported more frequently in the nivolumab arm (5% any grade and 1% grade 3 or 4) than the docetaxel arm (0% any grade).
No treatment-related deaths occurred in patients treated with nivolumab, and three treatment-related deaths occurred on the docetaxel arm. The second phase III trial, CheckMate 057, was conducted in 582 patients with a nonsquamous histology who had experienced progression on prior platinum-based doublet therapy ( Table 2) . 37a Prior tyrosine kinase inhibitors were allowed for a known ALK translocation or EGFR mutation. The primary end point was OS. A preplanned interim analysis showed that both median OS (12.2 months for nivolumab v 9.4 months for docetaxel; HR, 0.73; 95% CI, 0.59 to 0.89; P = .0015) and 1-year OS (51% for nivolumab v 39% for docetaxel; Table 2 ) were improved in patients receiving nivolumab compared with docetaxel. The ORR was 19% for nivolumab and 12% for docetaxel (P = .0246). Although the median PFS nonsignificantly favored docetaxel (2.3 months for nivolumab v 4.2 months for docetaxel; P = .3932), the median DOR was 17.2 months for patients treated with nivolumab compared with 5.6 months in the docetaxel arm. Forest plots from an unplanned subgroup analysis indicate that patients who had never smoked (n = 118; HR, 1.02; 95% CI, 0.64 to 1.61) and those with EGFR mutations (n = 82; HR, 1.18; 95% CI, 0.69 to 2.00) are unlikely to benefit from nivolumab. Increased PD-L1 expression ($ 1%, $ 5%, and $ 10%) correlated with improved PFS and OS and low PD-L1 expression (, 1%, , 5%, and , 10%) correlated with comparable OS and inferior PFS for nivolumab compared with docetaxel ( Table 3 ). The interaction P values between PD-L1 expression and nivolumab benefit were significant at all expression levels for PFS and OS except less than 1% (P = .0646). Treatmentrelated AEs of any grade occurred in 69% and 88% of patients and grade 3 or 4 AEs occurred in 10% and 54% of patients receiving nivolumab and docetaxel, respectively ( Table 4 ). The most common treatment-related AEs of any grade reported for nivolumab were fatigue (16%), nausea (12%), and decreased appetite (11%). Pneumonitis was more common on the nivolumab arm (3% any grade and 1% grade 3 or 4) than on the docetaxel arm (, 1% any grade and , 1% grade 3 or 4). No deaths from pneumonitis were reported, although one death was attributed to nivolumab (encephalitis).
Pembrolizumab (PD-1): Phase I and II Trials
Pembrolizumab has been studied in three phase I/II trials for the treatment of second-line and beyond NSCLC, either alone or in combination with immunotherapy ( Table 2) . [39] [40] [41] The phase I dose-escalation KEYNOTE-001 trial was designed to evaluate the efficacy of pembrolizumab at doses of 2 mg/kg every 3 weeks (n = 6), 10 mg/kg every 3 weeks (n = 287), or 10 mg/kg every 2 weeks (n = 202) in patients with advanced NSCLC overall (N = 495), as well as in those with higher levels of PD-L1 expression (proportional score [PS] $ 50%). 39 Median PFS and OS were 3.7 months and 12.0 months, respectively, for patients overall, and 3.0 months and 9.3 months, respectively, for previously treated patients ( Table 2 ). The ORR was 19.4%, which included a response rate of 18% in 394 previously treated patients. Response outcomes were significantly higher in patients with PD-L1 PS $ 50% expression compared with patients expressing lower levels (PS of 1% to 49% or PS , 1%) in both the pretreated (P ,.001) and untreated populations (P = .01; Table 3 ), and PFS and OS times were shorter among patients with lower levels of expression compared with those expressing PD-L1 at higher levels. In the whole population, treatment-related AEs of grade 3 or greater were reported in 9.5% of patients. Immune-mediated pneumonitis of any grade was reported in 3.6% of patients, grade 3 or 4 pneumonitis was reported in 1.8% of patients, and it was fatal in one patient (0.2%). No differences in outcomes were seen between the doses or schedules studied, and a fixed dose of pembrolizumab 200 mg every 3 weeks will be used for further study. 50,51 Preliminary findings from ongoing studies evaluating the benefits of pembrolizumab in patients (n = 16) with advanced NSCLC and untreated brain metastases are promising (brain metastasis and systematic response rates were both 45%), 41 and OS results from the randomized phase II/III KEYNOTE-010 trial in patients with PD-L1-positive NSCLC will establish the role of pembrolizumab as second-line therapy ( Table 5 ). 51a Cohort D of the randomized phase I/II KEYNOTE-021 trial explored the optimal dosing of a combination of pembrolizumab and the CTLA-4 checkpoint inhibitor ipilimumab in patients with advanced NSCLC who had experienced treatment failure with at least one prior platinum doublet ( Table 2) . 40 Various dose combinations were assessed in 18 evaluable patients, and no doselimiting toxicities were observed. Grade $ 3 AEs occurred in 83% of patients, but no treatment-related grade 4 AEs or deaths were observed. A single case of grade 1 pneumonitis was reported (6%), and ORRs across all doses were 39%. Pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg every 3 weeks had a manageable toxicity profile. The combination will be further evaluated in an expansion cohort. 52
PD-L1 Inhibitors
PD-L1 checkpoint inhibitors currently under development for NSCLC are fully human or humanized immunoglobulin G1 anti-PD-L1 antibodies that specifically inhibit the binding of PD-1 to its ligand PD-L1, restoring tumor-specific T-cell immunity while theoretically leaving the PD-1/PD-L2 pathway intact. 44,53-56 Multiple PD-L1 inhibitors have shown activity in NSCLC. 42-47,47a Atezolizumab (PD-L1): Phase I and II trials. One phase I trial 43 and two phase II trials 44,47a have evaluated atezolizumab in NSCLC ( Table 2) . The phase II, multicohort, FIR trial assessed the safety and efficacy of atezolizumab at a dose of 1,200 mg every 3 weeks in PD-L1-selected patients receiving firstor second-line treatment for advanced NSCLC, either with or without brain metastases. 44 Of the 105 evaluable second-line patients, response rates of 23% and 16% and median OS times of 6.8 and 10.6 months were seen for patients with and without brain metastases, respectively. Grade 3 or 4 treatment-related AEs occurred in between 15% and 17% of pretreated patients, and low rates of pneumonitis were reported across all cohorts (n = 1).
The phase II POPLAR trial randomly assigned 287 patients with squamous (34%) and nonsquamous (66%) NSCLC who had experienced progression on prior platinum-based therapy to receive atezolizumab 1,200 mg every 3 weeks or docetaxel 75 mg/kg every 3 weeks (Table 2 ). 47a Primary end point was OS in PD-L1selected and intent-to-treat populations. At a planned interim analysis conducted with a median follow-up of 12 months, median OS was 11.4 months for patients receiving atezolizumab versus 9.5 months for patients receiving docetaxel (HR, 0.77; 95% CI, 0.55 to 1.06; P = .11). The median PFS was not markedly different for atezolizumab compared with docetaxel (2.8 v 3.4 months, respectively; HR, 0.98). ORRs were comparable for both the atezolizumab and docetaxel groups (15%), but the median DOR at the time of the analysis was longer for atezolizumab (not yet reached) compared with docetaxel (7.8 months). Results indicated a significant trend toward improved OS and a trend toward improved PFS for atezolizumab with increased PD-L1 expression ( Table 3 ). Treatmentrelated grade 3 or 4 AEs were rarer with atezolizumab (12%) compared with docetaxel (39%), and the rate of grade 5 AEs as a result of any cause was 4% in each arm ( Table 4 ). The most common treatment-related AEs of any grade reported for atezolizumab were decreased appetite (approximately 33%), dyspnea (approximately 27%), and nausea (approximately 22%). Pneumonitis of any grade was reported in 2% of patients. Results of the ongoing randomized phase III OAK trial will determine the role of atezolizumab in the second-line setting ( Table 5 ). 59 Durvalumab (PD-L1): Phase I trial. Durvalumab has been evaluated alone and in combination with immunotherapy in two phase I trials for advanced NSCLC (Table 2) . 45, 46 The first trial assessed single-agent durvalumab in 228 heavily pretreated patients. 45 ORRs were 16% overall and 19% for second-line patients. The response rate in PD-L1-positive tumors was 27%, and treatment-related grade 3 or 4 AEs occurred in 8% of patients. Pneumonitis of any grade was seen in 1% of patients, and no grade 3 or 4 pneumonitis was reported. Another phase I trial evaluated durvalumab plus immunotherapy. 46 Durvalumab in combination with tremelimumab demonstrated activity (ORR, 27%) in 102 patients with advanced NSCLC who experienced treatment failure with prior therapy ( Table 2 ). 46 Response rates were higher in PD-L1-positive (33%) compared with PD-L1negative (27%) tumors.
Avelumab (PD-L1): Phase I trial. A phase IB expansion trial assessed avelumab in patients with advanced NSCLC who experienced progression on platinum-based therapy (n = 184; Table 2 ). 47 The ORR was 13.6% in patients overall, and the median OS was 8.4 months. There was a trend toward improved ORR and median OS with increased PD-L1 expression. Treatment-related grade $ 3 AEs occurred in 12.5% of patients, and two treatment-related deaths were reported. Recruitment to a first-line NSCLC cohort and the randomized JAVELIN Lung 200 phase III trial will further characterize the benefits of avelumab compared with docetaxel in advanced PD-L1-positive second-line disease ( Table 4 ). 60
DISCUSSION

How Do Checkpoint Inhibitors Compare With Standard Second-Line Therapy in Terms of Efficacy?
Docetaxel is a standard second-line treatment option for patients with squamous NSCLC or patients with nonsquamous disease and a mutation status that is negative or unknown. There are currently results from three randomized trials comparing PD-1/PD-L1 inhibitors to docetaxel, 37,37a,47a although the POP-LAR trial may have been underpowered to show benefit from atezolizumab, 47a and results from a fourth trial are expected by the end of the year. 51a There is level 1 evidence suggesting improved efficacy with nivolumab in both squamous and nonsquamous populations for the second-line treatment of advanced NSCLC, 37,37a although initial crossover of OS and PFS curves from the CheckMate 057 trial suggest that patient selection in nonsquamous populations might be particularly important. 37a Checkpoint inhibitors in patients with brain metastases or a performance status greater than 2 should be considered carefully as a result of a lack of randomized data, and patients with immunerelated diseases on high-dose corticosteroids may not be candidates for this class of agents. 28
How Do Checkpoint Inhibitors Compare With Standard Second-Line Therapy in Terms of Safety?
Checkpoint inhibitors are associated with a unique set of AEs as a result of nonspecific immunologic activation, 18 and early reports suggest that these are related to the infiltration of highly activated CD4 and CD8 T cells, resulting in the increased production of inflammatory cytokines in otherwise healthy tissues. 61 In both the CheckMate 057 and 017 trials, 37,37a rates of treatmentrelated AEs of any grade (58% to 69% for nivolumab v 86% to 88% for docetaxel) as well as grade 3 or 4 AEs (7% to 10% for nivolumab v 55% to 69% for docetaxel) were lower for nivolumab compared with docetaxel ( Table 3 ). The most common treatmentrelated AEs associated with nivolumab in both trials were fatigue (16%), nausea (9% to 12%), decreased appetite (11%), and asthenia (10%), and those associated with docetaxel were neutropenia (31% to 33%), fatigue (29% to 33%), nausea (23% to 26%), alopecia (22% to 25%), and diarrhea and anemia (20% to 23%). Continued vigilance of immune-related AEs at the physician, nurse, and patient level, as well as a proactive, multidisciplinary AE management strategy will be important for ensuring quality care.
Pneumonitis is a potentially serious AE that can be life threatening, resulting in hospitalization and requiring cessation of therapy. 62 Early clinical trial reports identified pneumonitis as a potential concern for PD-1 inhibitors, 33,39,63 and recent randomized data from the CheckMate 017 (5% any grade) and CheckMate 057 trials (3% any grade and 1% grade 3 or 4) have confirmed the risk of this AE with nivolumab therapy. 37,37a It has been hypothesized that rates of pneumonitis might be lower with use of PD-L1 inhibitors, as a result of the potential importance of the PD-1/PD-L2 interaction in the negative regulation of autoimmune responses. 55, 56 Early signals from phase I/II PD-L1 inhibitor trials suggested the potential for reduced pneumonitis with atezolizumab (0.7% grade 3 or 4) 44 and durvalumab (1% any grade). 45 However, randomized data from the POPLAR trial suggest that rates (2% any grade) are likely to be more comparable to PD-1 inhibitors than first expected. 47a
Should Patients With a Known Mutation Be Treated With Checkpoint Inhibitors?
The standard of care for the second-line treatment of patients with known mutations is either platinum-based chemotherapy and/or targeted therapy. There are currently no phase III trials comparing checkpoint inhibitors with standard second-line therapy in patients with known mutations. The CheckMate 057 study conducted in nonsquamous NSCLC compared nivolumab with docetaxel and included a minority of patients with known mutations (14% EGFR mutations and 3% to 4% ALK translocations). 37a Although OS outcomes favored nivolumab overall, an examination of forest plots indicated a trend toward a lack of benefit in never-smokers (n = 118; HR, 1.02; 95% CI, 0.64 to 1.61) and patients with EGFR mutations (n = 82; HR, 1.18; 95% CI, 0.69 to 2.00), although this study was not powered for such an analysis. Further analysis of completed and ongoing trials will clarify the role of checkpoint inhibitors in patients with driver mutations or particular smoking histories.
Should PD-L1 Expression Be Used to Guide Treatment
With Anti-PD-1 or Anti-PD-L1 Therapy?
Biomarker research has been a central part of many clinical trials evaluating PD-1 or PD-L1 inhibitors for NSCLC. 33,37,37a,43,45,47,64 Given that docetaxel is generic in many countries, 65,66 the higher cost of immunotherapy can be assumed. Therefore, identifying a proper biomarker will be integral to managing overall costs. The most commonly investigated biomarker for checkpoint inhibitors today is PD-L1 expression. Subgroup analyses designed to assess the correlation between PD-L1 expression and checkpoint inhibitor outcomes in randomized trials have shown conflicting results. The PD-L1 analysis of the CheckMate 017 trial showed no relationship between PD-L1 expression and PFS or OS, whereas analyses of the CheckMate 057, POPLAR, and KEYNOTE-001 trials demonstrated trends toward improved outcomes with increasing levels of PD-L1 expression ( Table 3 ). In some instances, substantial increases in ORR were observed with increasing levels of PD-L1 expression (pembrolizumab, 10.7% v 45.2% for PS , 1% v PS $ 50%, respectively). 67 It is unclear whether the observed variability is a result of differences in the type of checkpoint inhibitor used (anti-PD-1 v anti-PD-L1), clinicopathologic attributes of the populations tested (eg, squamous v nonsquamous, smoking v nonsmoking), approaches to PD-L1 testing (eg, multiple immunohistochemistry antibodies, tumor v tumor plus stroma, fresh v archival biopsy, histology v cytology), other testing considerations (eg, scoring technique and cutoff values), or methodology (eg, primary v secondary end point, randomized v not, high v low representation, stratified v not, validated cutoff v not). [68] [69] [70] Differences in PD-L1-dependent outcomes may be explained by differences in tumor mutational load in the respective trials. Immunotherapy is highly active and has durable clinical benefit in patients with higher mutational burden and distinct smoking molecular signatures. 71 Because squamous populations are more likely to be smokers and have higher mutational loads, it is not surprising that there is a significant and uniform benefit from immunotherapy in these patients and less benefit from PD-L1 selection. By contrast, nonsquamous populations tend to be more heterogeneous, with a lower proportion of smokers (lower mutational load) and a greater proportion of patients with oncogenic driver mutations (ie, EGFR mutations). Benefit from immunotherapy could therefore be more varied in these patients and the need for PD-L1 patient selection greater. Outcomes from the more methodologically rigorous OAK and KEYNOTE-010 trials, which stratify patients according to PD-L1 status, will improve our understanding of the role of PD-L1 selection in second-line NSCLC. 51a,59 Are There Unique Clinical Response Patterns With the Use of Checkpoint Inhibitors in NSCLC?
Clinical response patterns of immunotherapeutics show unique outcome signatures. In randomized trials conducted in NSCLC, response rates are not always substantially improved with checkpoint inhibitors compared with controls, 37,37a despite the often observed durable responses. For instance, nearly 2.7% of patients in the CheckMate 057 trial experienced nonconventional responses to nivolumab (ie, did not meet Response Evaluation Criteria in Solid Tumors [RECIST] ). 37a This may in part be explained by the infiltration of tumor lesions by immune and inflammatory cells, which may be mistaken as tumor growth or progression on imaging. 72 Immune-related response criteria have been developed that account for these unique patterns. 72 However, unlike melanoma, their adoption in NSCLC trials has been limited because pseudo-progression events are relatively rare in this setting. 73 Patients who respond to checkpoint inhibitors can experience durable responses that may lead to long-term survival, 74 which calls into question the suitability of median OS as the best efficacy metric. One-and 2-year OS may be more suitable indicators of efficacy for this class of agents in NSCLC.
What Is the Direction of Ongoing Checkpoint Inhibitor Research?
The landscape of immunotherapy for NSCLC is rapidly evolving ( Table 4 ). Multiple randomized trials are under way evaluating PD-1, PD-L1, and CTLA-4 inhibitors in combination with chemotherapy in the firstor second-line setting (Table 4) , with additional studies addressing the use of these agents in early-stage disease (ClinicalTrials.gov identifiers: NCT02273375 and NCT02125461). Randomized trials assessing the benefits of immunotherapeutics in combination with targeted therapy are ongoing (NCT02366143 and NCT02454933), 38 as are those investigating immunotherapy combinations (NCT02352948 and NCT02453282). 75
Summary
Level 1 evidence currently supports use of nivolumab as second-line NSCLC therapy in patients with squamous histology, as well as in select patients with nonsquamous disease. The benefit of this class of drugs in patients with targetable driver mutations remains uncertain. The use of PD-L1 expression to guide therapy in NSCLC is controversial, as illustrated by the approval of nivolumab in squamous NSCLC regardless of PD-L1 status and the approval of pembrolizumab in PD-L1-positive patients. Although PD-L1 expression remains the best available biomarker for these patients, further validation and standardization are needed to effectively guide therapy. The field of immunotherapeutic research is rapidly evolving, and research into other checkpoint inhibitors, new combinations, biomarkers, and use in earlier settings is ongoing.
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